https://www.selleckchem.com/products/dzd9008.html
Gemtuzumab ozogamicin (GO) was approved in 2017 in the US for the treatment of adults with newly diagnosed CD33-positive (CD33+) acute myeloid leukemia (AML), and adults and pediatric patients with CD33+ relapsed/refractory (R/R) AML. The aim of this study was to estimate the budgetary impact of introducing GO to a 1-million-member US health plan over a 5-year period. We developed models to estimate the impact of introducing GO in combination with conventional induction chemotherapy or as monotherapy for newly diagnosed AML, and as mono
Like
Comment
Share
